NL-OMON50242招募中3 期
eoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer - SANO trial: *Surgery As Needed for Oesophageal cancer*
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 738
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients who are planned to undergo or who recently underwent neoadjuvant
- •chemoradiotherapy according to CROSS, followed by surgical resection for
- •histologically proven oesophageal squamous cell carcinoma or adenocarcinoma of
- •the oesophagus or oesophago-gastric junction;, Age >=18;, Written, voluntary,
- •informed consent.
排除标准
- •Language difficulty, dementia or altered mental status prohibiting the
- •understanding and giving of informed consent and to complete quality of life
- •questionnaires;, Non-FDG-avid tumour at baseline PET-CT scan.
- •Previous treatment with endoscopic resection.
研究者
相似试验
已完成
Unknown
eoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer<p>Oesophageal cancer, oesofaguscarcinoom, esophageal cancer, active surveillance</p>10017998NL-OMON25016Erasmus MC300
招募中
3 期
Cancer injection before surgery vs after surgery in stomach cancerCTRI/2021/01/030183Jawaharlal Institute of Postgraduate Medical Education and Reserach
进行中（未招募）
1 期
Chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastasesThe CHARISMA randomized multicenter clinical trialEUCTR2013-004952-39-NLErasmus MC Cancer Institute224
已完成
3 期
eo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases ;The CHARISMA randomized multicenter clinical trialLiver metastases colorectal cancer1001981510017998NL-OMON44796Erasmus MC, Universitair Medisch Centrum Rotterdam224
尚未招募
不适用
Chemotherapy followed by versus surgery alone in high-risk patients with colorectal liver metastasesColorectal liver metastases, clinical risk score, high risk patients, colorectale levermetastasen, klinische risico score, hoog risico patientenNL-OMON27498Prof. Dr. C. VerhoefErasmus MC Cancer Institute224